Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 21.6% - Should You Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price was up 21.6% on Wednesday . The company traded as high as $4.93 and last traded at $4.83. Approximately 21,567,297 shares traded hands during mid-day trading, a decline of 7% from the average daily volume of 23,082,207 shares. The stock had previously closed at $3.97.

Analysts Set New Price Targets

RXRX has been the subject of several recent analyst reports. Needham & Company LLC restated a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Morgan Stanley cut their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday. KeyCorp decreased their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Finally, Leerink Partners cut their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Recursion Pharmaceuticals currently has an average rating of "Hold" and a consensus target price of $8.20.

Recursion Pharmaceuticals Stock Up 27.7 %

The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company has a fifty day simple moving average of $6.83 and a two-hundred day simple moving average of $6.84. The firm has a market capitalization of $2.32 billion, a PE ratio of -3.76 and a beta of 1.00.

Remove Ads

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. During the same quarter in the previous year, the company earned ($0.42) earnings per share. The firm's revenue was down 57.8% on a year-over-year basis. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently bought and sold shares of RXRX. Ensign Peak Advisors Inc increased its holdings in shares of Recursion Pharmaceuticals by 0.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock valued at $2,774,000 after acquiring an additional 1,300 shares during the period. Farther Finance Advisors LLC grew its stake in Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after purchasing an additional 1,353 shares during the last quarter. Summit Investment Advisors Inc. raised its holdings in Recursion Pharmaceuticals by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock worth $176,000 after purchasing an additional 1,875 shares in the last quarter. Wedmont Private Capital lifted its position in shares of Recursion Pharmaceuticals by 10.6% during the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company's stock valued at $144,000 after buying an additional 2,000 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 28.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company's stock valued at $69,000 after buying an additional 2,235 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.